What factors could disrupt AMGN's 2025 revenue?

Several factors could potentially disrupt Amgen's 2025 revenue: 1. **Tariff and Patent Concerns**: The biopharmaceutical sector is facing challenges due to new U.S. tariffs and the patent cliff. These factors could lead to earnings pressure for innovative pharmaceutical companies like Amgen, ranging from 6% to 14% if a 25% U.S. tariff is implemented. 2. **Part D and Inflation Reduction Act**: The impact of the Part D and Inflation Reduction Act could also influence Amgen's financial performance. These legislative changes might affect tax rates and overall industry dynamics, potentially impacting the company's revenue and margins. 3. **Competition from Biosimilars**: Amgen faces competition from biosimilars, which could impact its market share and pricing power. The company's strong market positioning with a diverse portfolio of biologics and biosimilars is a key risk, as indicated by the Franklin Biotechnology Discovery Fund's Q2 2024 commentary. 4. **Regulatory Challenges**: The biotech landscape is fraught with regulatory challenges, which could delay or prevent the approval of new products. This could impact Amgen's future revenue growth. 5. **Market Conditions and Competition**: The biopharmaceutical market is highly competitive, and Amgen's ability to maintain its market position and pricing power could be disrupted by competitive pressures from other companies. In summary, Amgen's 2025 revenue could be disrupted by tariff and patent concerns, regulatory challenges, competition from biosimilars, and market conditions. These factors could lead to earnings pressure, impact market share, and affect the company's overall financial performance.